The presence of 40 % BRAF and KRAS mutations in the context of 71–90 % estimated tumor cellularity in case P4 and the presence of 31 % BRAF mutation and 30 % KRAS mutation in the context of 51–70 % estimated tumor cellularity in case P5 suggest that the kinase-impaired BRAF mutation and the activating KRAS mutation were present in the all the tumor cells. The gene discussed is BRAF; the disease is neoplasm.